Hypobaric hypoxia environments present a major concern after ascending to high altitudes (2,500+ meters) because the immune system's inability to adapt to sudden changes in O2 concentration quickly, causing tissue hypoxia if left untreated and leading to the development of high altitude illnesses (HAI). Acute altitude illnesses (AAS) and chronic altitude illnesses (CAI) are the two main types of HAI. AAS is subdivided into acute mountain sickness (AMS), chronic kidney disease (CKD), high altitude cerebral edema (HACE), and high altitude pulmonary edema (HAPE), while CAI is subdivided into chronic mountain sickness (CMS) and high altitude pulmonary hypertension (HAPH). Given that over 140 million people live permanently at elevations of 2,500 meters or higher, and that 40 million people visit such locations on a seasonal basis, it's easy to see why studying the pathophysiology, mechanism, and treatment of such diseases has become critical. Although many genes are affected by high altitude hypoxia, the focus of this review was on the role of five specific genes and proteins (HIF-1, EPAS1/HIF-2, VEGF, P53, and VHL), whose expression is influenced by hypoxia and immunological changes in human response to immune-mediated inflammatory diseases (IMIDs), microbiota diversity in the gut, and physiological changes in the blood.